======================================================================
GLP-1 RECEPTOR AGONISTS: ADVERSE EVENT ANALYSIS SUMMARY
======================================================================

Analysis Date: 2026-02-03 17:31:52
Total Records Analyzed: 657

--------------------------------------------------
REPORT COUNTS BY DRUG AND ADVERSE EVENT
--------------------------------------------------

Semaglutide: 277 total reports
  - Thyroid Cancer: 11 reports
  - Pancreatitis: 266 reports

Tirzepatide: 59 total reports
  - Thyroid Cancer: 4 reports
  - Pancreatitis: 54 reports
  - Gastroparesis: 1 reports

Liraglutide: 321 total reports
  - Thyroid Cancer: 18 reports
  - Pancreatitis: 302 reports
  - Gastroparesis: 1 reports

--------------------------------------------------
YEAR-OVER-YEAR TRENDS
--------------------------------------------------

Semaglutide:
  - Pancreatitis: 55.4% increase (2024: 74 -> 2025: 115)
  - Thyroid Cancer: 500.0% increase (2024: 1 -> 2025: 6)

Tirzepatide:
  - Pancreatitis: 60.0% increase (2024: 20 -> 2025: 32)
  - Thyroid Cancer: 0.0% decrease (2024: 2 -> 2025: 2)

Liraglutide:
  - Pancreatitis: 50.0% increase (2024: 4 -> 2025: 6)
  - Thyroid Cancer: 50.0% decrease (2021: 2 -> 2024: 1)

--------------------------------------------------
SEVERITY ANALYSIS
--------------------------------------------------

Semaglutide (n=277):
  - Death: 10 (3.6%)
  - Hospitalization: 168 (60.6%)
  - Other Serious: 81 (29.2%)
  - Non-Serious: 18 (6.5%)

Tirzepatide (n=59):
  - Death: 3 (5.1%)
  - Hospitalization: 30 (50.8%)
  - Other Serious: 19 (32.2%)
  - Non-Serious: 7 (11.9%)

Liraglutide (n=321):
  - Death: 5 (1.6%)
  - Hospitalization: 150 (46.7%)
  - Other Serious: 146 (45.5%)
  - Non-Serious: 20 (6.2%)

--------------------------------------------------
KEY FINDINGS
--------------------------------------------------

1. Pancreatitis reports: Liraglutide has the highest count (302 reports)

2. Thyroid cancer reports: Liraglutide has the highest count (18 reports)

3. Hospitalization rate: Semaglutide has the highest rate (63.5%)

4. Mortality rate: Tirzepatide has the highest rate (5.1%)

======================================================================
END OF SUMMARY
======================================================================